Dr Reddy’s shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
The shares of Dr Reddy’s Laboratories tumbled another 4% on Friday, extending their decline to more than 9% over two days after the company said commercial supplies of its semaglutide product would be delayed due to a quality-related issue involving the active pharmaceutical ingredient (API) used in certain batches. The pharma company’s shares fell to…